Trial reportBMC psychiatry2026
Amygdala neurofeedback as an adjunct to residential dialectical behavior therapy for borderline personality disorder: a pilot randomized controlled trial.
Trial report in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04333888 (BrainBoost - A Neurofeedback Booster for Emotion Regulation Therapy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
BrainBoost - A Neurofeedback Booster for Emotion Regulation Therapy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBorderline personality disorder (BPD) is characterized by affective instability and amygdala hyperreactivity. Although dialectical behavior therapy (DBT) reduces symptoms and amygdala-related abnormalities, many patients show only partial remission. Real-time functional magnetic resonance imaging (fMRI) amygdala neurofeedback (amy-NF) directly targets hyperactive limbic responses and has shown promise in uncontrolled trials. We examined whether amy-NF adds benefit to inpatient DBT.
methodsThirty-six mid-therapy people with BPD and clinically significant residual symptoms (BSL-23 > 1.5) were randomized to DBT plus amy-NF (n = 23) or DBT alone, termed treatment as usual (TAU = 13). Post-treatment assessments were completed by 15/9 (amy-NF/TAU), with 15/8 and 12/7 completing the 3- and 6-month follow-ups. Ecological momentary assessment (EMA) of daily-life affective instability served as the primary outcome. Secondary outcomes included self-reports, amygdala responses during two fMRI tasks, and resting-state fMRI. Assessments occurred at pre-, post-, 3-, and 6-month follow-up.
resultsParticipants successfully downregulated amygdala activity during neurofeedback. EMA showed improvements in negative affect, inner tension, and affective instability over time, without consistent superiority of amy-NF. Self-reports likewise showed no additional benefit of amy-NF, and BSL-23 scores increased after discharge in both groups. Amy-NF was associated with transient pre-post reductions in amygdala activity during both viewing and regulation in the emotion regulation task, and with more stable amygdala reactivity over time than TAU in the faces task. Resting-state analyses showed transient pre-post increases in amygdala connectivity with precuneus and dorsomedial frontal regions in amy-NF.
conclusionsAmygdala neurofeedback is feasible and reduced amygdala activity in BPD, but did not yield additional clinical benefit when delivered alongside intensive residential DBT, although the small sample may have limited power to detect such effects.
trial registrationThe study protocol was preregistered 2020/03/26 on ClinicalTrials.gov and received the ID NCT04333888.
Indexed as
Identifiers
42888408What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.